US Gilead Sciences is aware of “positive data” from one of its studies looking at antiviral drug remdesivir as a potential treatment for the novel coronavirus.
The company also released data from its clinical trial involving patients with severe cases of Covid-19.
The severe study is “single-arm,” meaning it will not evaluate the drug against a control group of patients who didn’t receive the drug.
The study tracked two groups of patients who were hospitalized with Covid-19. One group received a 5-day treatment of remdesivir, while the other took the drug for 10 days. The researchers said more than half of the patients in both treatment groups were discharged from the hospital by 14 days.
here are no proven treatments for Covid-19, which has infected more than 3 million people worldwide and killed at least 217,569 as of Wednesday morning, according to data compiled by Johns Hopkins University.
